Glycyx is developing small molecule modulator therapies that counteract the negative effects of opioids on the efficacy of anti-PD1/PD-L1 immunotherapy in cancer patients. By enhancing gut permeability and immune response, these therapies aim to improve survival rates and quality of life for patients undergoing cancer treatment.
Funding
$3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Opioid use in cancer patients undergoing anti-PD1/PD-L1 immunotherapy can negatively impact the efficacy of the immunotherapy treatment. This interference reduces the effectiveness of the cancer treatment, potentially lowering survival rates and quality of life.
Solution
Glycyx is developing small molecule modulator therapies designed to counteract the negative effects of opioids on anti-PD1/PD-L1 immunotherapy in cancer patients. These therapies aim to enhance gut permeability and improve immune response, thereby maximizing the effectiveness of the immunotherapy. By reversing the opioid-induced interference, Glycyx's therapeutic solution ensures that pain management does not compromise the cancer treatment's ability to improve survival rates and quality of life. The company is focused on pioneering a novel therapeutic approach to address this overlooked issue in oncology.
Target Audience
The primary target audience includes cancer patients undergoing anti-PD1/PD-L1 immunotherapy who also require opioid pain management, as well as the oncologists treating these patients.
Features
- Small molecule modulators designed to reverse the negative impact of opioids.
- Therapies enhance gut permeability to improve drug absorption.
- Modulation of immune response to maximize immunotherapy effectiveness.
- Designed for use in conjunction with anti-PD1/PD-L1 cancer treatments.